Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan Combined With Radiotherapy in HER2-Mutated Oligoprogressive Advanced NSCLC
NCT07781202Phase 2Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Aug 2029
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in non-small cell lung cancer (NSCLC). Primary endpoint: Incidence of Grade >=3 interstitial lung disease at 12 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07781202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07781202.